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Abstract 
Background: Rifampicin or rifampin (R) is a common drug used to treat inactive meningitis, cholestatic pruritus and 
tuberculosis (TB), and it is generally prescribed for long-term administration under regulated dosages. Constant moni-
toring of rifampicin is important for controlling the side effects and preventing overdose caused by chronic medica-
tion. In this study, we present an easy to use, effective and less costly method for detecting residual rifampicin in urine 
samples using protein (bovine serum albumin, BSA)-stabilized gold nanoclusters (BSA-Au NCs) adsorbed on a paper 
substrate in which the concentration of rifampicin in urine can be detected via fluorescence quenching. The intensity 
of the colorimetric assay performed on the paper-based platforms can be easily captured using a digital camera and 
subsequently analyzed.
Results: The decreased fluorescence intensity of BSA-Au NCs in the presence of rifampicin allows for the sensitive 
detection of rifampicin in a range from 0.5 to 823 µg/mL. The detection limit for rifampicin was measured as 70 ng/
mL. The BSA-Au NCs were immobilized on a wax-printed paper-based platform and used to conduct real-time moni-
toring of rifampicin in urine.
Conclusion: We have developed a robust, cost-effective, and portable point-of-care medical diagnostic platform for 
the detection of rifampicin in urine based on the ability of rifampicin to quench the fluorescence of immobilized BSA-
Au NCs on wax-printed papers. The paper-based assay can be further used for the detection of other specific analytes 
via surface modification of the BSA in BSA-Au NCs and offers a useful tool for monitoring other diseases.
Keywords: Fluorescent biosensors, Fluorescence quenching, Gold nanocluster, Rifampicin detection, TB drug 
monitoring, Wax-printed paper platform
© 2015 Chatterjee et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Rifampicin is an important bactericidal antibiotic drug 
of the rifamycin group, which inhibits DNA-dependent 
RNA polymerase and suspends bacterial growth. This 
drug is widely used to target Bacillus and Listeria strains 
and commonly prescribed together with other drugs 
for the treatment of tuberculosis (TB) [1–3] and infec-
tions associated with osteomyelitis, prosthetic joints, and 
meningitis. In the treatment of TB, three frontline drugs, 
isoniazid (INZ), ethambutol (E) and pyrazinamide (P), 
are given together with rifampicin. In a standard treat-
ment procedure for TB, all four drugs are administered in 
various combinations over the first 2 months, and isonia-
zid and rifampicin are continued for the next 4 months 
[1]. Improper dosage during the sustained medication 
period (2–6  months) often leads to drug resistance and 
even death despite the diseases being curable. Therefore, 
it is necessary to monitor possible irregularities in drug 
dosage. The simplest approach for detecting irregular-
ity in drug dosage is to assess the residual rifampicin in 
the urine of patients; however, inaccurate results could 
adversely affect the patient and lead to an increased risk 
of hepatotoxicity because of increased ingestion and 
drug accumulation in the liver. Thus, various methods 
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have been applied to detect rifampicin levels, including 
spectrophotometry [4], chemiluminescence [5], electro-
chemistry [6], and high-performance liquid chromatog-
raphy (HPLC) [7–11]. However, it is desirable to develop 
an alternative approach for on-site detection of residual 
rifampicin in urine. Recently, a paper-based sensing plat-
form was demonstrated as an attractive alternative to 
conventional analytical instrumentation for point-of-care 
medical diagnostics [12, 13], and it is ideal for the detec-
tion of residual rifampicin in urine because of its advan-
tages, including its low cost, quick response time, ease of 
handling and disposability. However, the selectivity and 
sensitivity of paper-based sensors are highly dependent 
on the sensing scheme.
With recent developments in nanotechnology, nano-
particle-based sensors have demonstrated notably high 
sensitivity in various applications [14–19]. Fluorescent 
metal nanoclusters (NCs) [20–27] are a recent addition 
to a growing list of labeling and sensing agents that have 
generated massive interest among researchers because of 
their biocompatibility, non-toxicity and outstanding fluo-
rescent properties. Fluorescent gold nanoclusters manu-
factured via eco-friendly one-pot synthesis approaches 
using commonly available templating agents (i.e., bovine 
serum albumin (BSA) [20], lysozyme [21], rec1-resilin 
[22], transferrin [23], glutathione [24], insulin fibrils [25], 
horseradish peroxidase [26] and papain [27]) have been 
reported by several groups. Among these materials, BSA-
stabilized metal nanoclusters have been widely used as 
fluorescent turn-off probes for the detection of metho-
trexate (MTX) [28], quercetin [29], cyanide [30], glucose 
[31], Hg2+ [32], and Cu2+ in aqueous solution [33] and 
even Cu2+ in live cells [34]. To date, various NC applica-
tions have been reported as fluorescent probes used in 
the solution phase [28–34]. However, few studies [35] 
have explored the immobilization of NCs on paper and 
their subsequent use as a sensing platform. Based on the 
concept of paper chromatography, immobilized paper 
sensors have been used in modern laboratories for a 
number of years. However, applications with paper-based 
drug monitoring devices have not been fully explored.
In this experiment, a commercially available printer 
and hot plate were used to create multi-zone standard 
96-well paper microplates as an alternative to conven-
tional polymer multiwell plates [12, 13]. The fluorescent 
BSA-Au NCs were immobilized on a wax-printed paper 
platform in which the fluorescence intensity from the 
immobilized BSA-Au NC was quenched in the presence 
of rifampicin. Rifampicin exhibited a greater binding 
affinity with BSA than isoniazid, and the binding order 
of rifampicin with BSA is approximately 104 L/mol [36], 
whereas it is approximately 103 L/mol [37] with isoniazid. 
Therefore, the BSA-Au NC-modified paper sensor can be 
used to detect the residual rifampicin in urine. Figure 1 
presents a schematic of the preparation and detection 
strategy of the paper sensor for residual rifampicin in 
urine. The BSA-Au NC microplate paper sensor can be 
fabricated in three steps: printing patterns on the paper, 
Figure 1 Schematic illustration of the synthesis, BSA-Au NC immobilization on paper and application to detect rifampicin.
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melting wax to form hydrophobic barriers, and immobi-
lizing the BSA-Au NCs in the reaction zones. After drop-
ping the samples onto the paper sensor, the fluorescence 




The BSA-Au NCs were developed using alkaline co-
precipitation of gold salt with protein BSA [41], and 
they exhibited a sharp and intense emission peak cen-
tered at approximately 640 nm when excited at 480 nm 
(Additional file  1: Figure S1). The emission band cen-
tered at 640  nm began to appear after heating the 
reactants for approximately 10  min, and the emission 
intensity increased proportionally with 30  min of heat-
ing, although upon further heating, the intensity gradu-
ally decreased. Therefore, the optimal reaction time was 
30  min for the synthesis of fluorescent BSA-Au NCs at 
70°C at a pH of 11.5 (Additional file  1: Figure S1). The 
maximum fluorescence intensity of the emission peak 
of the BSA-Au NCs was obtained at an excitation wave-
length of 480 nm (Additional file 1: Figure S2). Thus, the 
selection of 480  nm as the excitation wavelength with 
an emission peak centered at 640  nm and large Stokes 
shift (greater than 150 nm) eliminated the possibility of 
fluorescence self-quenching and measurement errors 
that might be caused by excitation light and scattering. 
The quantum yield of the prepared BSA-Au NCs was 
approximately 2% compared with that of Rhodamine 6G. 
In addition, the prepared BSA-Au NCs showed excellent 
stability over a wide range of pH values (2.0–10.0) (Addi-
tional file 1: Figure S3).
Solid-state Fourier transform infrared spectroscopy 
(FTIR) spectra were analyzed to investigate the surface 
structural changes after conjugating Au with BSA. The 
FTIR spectrum (Additional file  1: Figure S4) confirmed 
the presence of amide A, amide I, and amide II bands 
at 3,302.09  cm−1, 1,661.14  cm−1 and 1,530.14  cm−1, 
respectively, in pure BSA. The spectra of the BSA-Au 
NCs also showed three prominent bands correspond-
ing to amide A, amide I, and amide II of the dipeptide at 
3,297.41 cm−1, 1,658.18 cm−1 and 1,531.34 cm−1, respec-
tively, which clearly demonstrated the dipeptide pres-
ence on the Au cluster surfaces. Additionally, a band at 
2,961.20  cm−1 corresponding to C–H vibrations modes 
observed in pure BSA can also be observed in BSA-Au 
NCs. After adding rifampicin to the NCs, the FTIR spec-
tra showed a considerable decrease in the broad band 
centered around 3,293.01. Although the characteristic 
peak of BSA at 3,293.01, 1,645.43 and 1,535.64 cm−1 were 
quite evident in the spectra (BSA-Au+R); peak broaden-
ing after the addition of rifampicin to the BSA-Au NCs 
could point towards the formation of hydrogen bond-
ing between rifampicin and the BSA-Au NCs. The FTIR 
analysis illustrated that the surface structure of BSA 
remained intact even after the formation of BSA-Au 
NCs, implying that the BSA retained its reactive sites on 
the surface and could be further modified with new func-
tional groups.
The size and shape of the BSA-Au NCs were investi-
gated via electron microscopy. Additional file 1: Figure S5 
presents the scanning transmission electron microscopy 
(STEM) (a) and high-resolution transmission electron 
microscopy (HRTEM) (b) images of the prepared BSA-
Au NCs. The STEM and HRTEM images indicate that 
the NCs are well dispersed and the average diameter of 
the BSA-Au NCs is approximately 1.1 ± 0.1 nm as calcu-
lated from the images via ImageJ (Additional file 1: Figure 
S6).
Matrix-assisted lasers desorption/ionization mass 
spectroscopy (MALDI-MS) analysis was performed to 
reveal the number of Au atoms in the BSA-Au NCs. The 
samples were dialyzed against water using a 10-kDa-
cutoff dialysis bag prior to MALDI-MS analysis. A broad 
peak for pure BSA was observed at m/z 65.4 kDa (Addi-
tional file  1: Figure S7a). After the reaction time was 
increased, the peaks for BSA-Au NCs became broader, 
and at a 30-min reaction time, we estimated that 18-atom 
Au NCs were formed (m/z 68.9) (Additional file 1: Figure 
S7b). The BSA undergoes partial denaturation upon heat-
ing at 70°C to expose amino residues, including histidine, 
cysteine, and tyrosine, which interact more strongly with 
Au+ (Au3+) to form NCs. Thus, one BSA conjugates with 
an 18-atom Au in the core to form BSA-Au NCs. The size 
of the formed Au cores is much smaller than that of BSA-
Au25NCs prepared at room temperature for 12  h [20] 
because of the higher energy provided for the formation 
of BSA-Au NCs. On addition of 10 mM rifampicin to the 
BSA-stabilized Au NC, the MS spectra indicate that the 
characteristic peak of the BSA-Au NCs remained intact, 
thus indicating that leaching of Au had not occurred 
from the core of the BSA-Au NCs (Additional file  1: 
 Figure S7c).
Quenching mechanism of BSA‑Au NCs by rifampicin
After adding rifampicin, the emission intensity of the 
NCs was greatly reduced. The MALDI-MS spectra 
(Additional file 1: Figure S7) of BSA-Au NCs both before 
and after adding rifampicin were quite similar, thus indi-
cating the absence of any leaching of Au from the core of 
the BSA-Au NCs. To further prove that Au is not leached 
from the core of the BSA-Au NCs, an inductively coupled 
plasma mass spectrometry (ICP-MS) (data not shown) 
analysis was performed to determine the Au content 
of the purified BSA-Au NCs both in the presence and 
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absence of rifampicin. The prepared aqueous solution of 
BSA-Au NCs had an Au content of 404.4 µg/mL, whereas 
upon interaction with rifampicin, 392.4 µg/mL of Au was 
detected in the aqueous solution of BSA-Au, revealing 
that the Au atoms in the NCs remained intact and were 
not filtered during dialysis.
Au is conjugated with BSA through covalent bonding 
between the Au and thiol groups of the cysteine in BSA 
[41]. Rifampicin does not substitute the BSA and drive 
Au NC aggregation, which is evident from the MALDI-
MS and ICP-MS data. Moreover, the absorption spec-
tra indicate that aggregation did not occur, even after a 
long period of time following the addition of rifampicin 
to BSA-Au NCs (Figure 2a). However, the interaction of 
BSA and rifampicin has been previously reported [36]. 
Therefore, BSA-Au NC quenching by rifampicin (Fig-
ure 2b) may have been caused by the interaction of BSA 
and rifampicin, which changes the environment of the 
Au NCs. Changes in the absorption spectra of BSA-Au 
NCs in the presence of rifampicin (shown in Figure 2a) 
are similar to those reported for the interaction of BSA 
and rifampicin alone [36]. The absence of aggregated Au 
NCs without BSA protection corroborates the formation 
of structures similar to the rifampicin-RS-Au bonds.
Particle size measurements might offer a more sensitive 
tool for studying nanoparticle aggregation and hydrody-
namic size distributions. BSA is a 66 kDa protein with a 
diameter of approximately 7–8  nm (data from Protein 
Data Bank). The dynamic light scattering (DLS) analysis 
could detect and measure the protein size directly (Addi-
tional file  1: Figure S8). The hydrodynamic size of BSA 
increases upon NC formation which can be conveni-
ently observed via DLS. The diameter of the BSA-Au NCs 
increases to at least two times the diameter of the protein 
(BSA) molecule. After adding rifampicin to the NC, the 
hydrodynamic size of the BSA-Au NCs further increased 
significantly (Additional file 1: Figure S8), indicating the 
bonding of rifampicin to the surface of the NC.
Fluorescence detection of rifampicin
With the inherent fluorescence of BSA-Au NCs and its 
high sensitivity, the synthesized NCs could be used to 
detect rifampicin via rapid fluorescence quenching. The 
fluorescence intensity of the BSA-Au NCs decreased 
proportionally with increases in rifampicin concentra-
tion (Additional file 1: Figure S9). As shown in Figure 3a, 
a nearly linear relationship was observed between the 
normalized decrease in fluorescence intensity (F0 − F)/F 
and concentration of rifampicin over a range from 0.5 to 
823 µg/mL. However, the normalized decrease in fluores-
cence intensity reached a plateau when the concentration 
of rifampicin fell below 0.5 µg/mL.
Plotting of the normalized decrease in fluorescence 
intensity (F0 − F)/F versus the log of the rifampicin con-
centration resulted in a linear calibration graph over the 
concentration range from 0.5 to 823 µg/mL (correlation 
coefficient: R2 = 0.9945) with a limit of detection (LOD) 
of 0.07  µg/mL (Figure  3b). The limit of quantification 
(LOQ) was 0.2 µg/mL. The reproducibility of the sensing 
system was established by performing three independ-
ent measurements using 20.6  µg/mL rifampicin with a 
relative standard deviation of 4.22% (R2 =  0.9948). This 
measurement was conducted to verify the reliability of 
the proposed method, which presents high sensitivity 
and notably low relative standard deviations.
Selectivity of BSA‑Au NCs toward detecting rifampicin
We tested the selectivity of BSA-Au NCs for sensing 
rifampicin in the presence of other antibiotics (INZ, E 
and P) used collaterally with rifampicin for the treatment 
Figure 2 a Absorption spectra of BSA-Au NCs (0.1× dilution) in the absence and presence of 10 µM rifampicin. b Fluorescence emission spectra 
(excitation wavelength at 480 nm) of BSA-Au NCs (0.1× dilution) in the absence and presence of 10 µM rifampicin.
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of TB. The fluorescent responses of BSA-Au NCs with 
all four antibiotics were monitored and compared with 
that of rifampicin. Figure  4a shows that the addition of 
rifampicin at a final concentration of 100  µM (83  µg/
mL) resulted in a nearly 90% decrease in the fluorescence 
intensity of the BSA-Au NCs, whereas a limited decrease 
in fluorescence intensity was observed for P (1.3%), 
INZ (2.8%) and E (6.5%) at the same molar concentra-
tion (Figure  4b). The clinical effectiveness of rifampicin 
as a primary drug for TB can mainly be attributed to 
4-methyl-1-piperazinaminyl substitution on rifampicin. 
Generally, antibiotics with piperazine moiety exhibit 
Figure 3 a Concentration-dependent quenching of BSA-Au NCs (0.1× dilution) by rifampicin. From higher to lower concentrations: normalized 
quenching at 823 µg/mL [(F0 − F)/F ~ 22.6 ± 0.68], 411 µg/mL [12.78 ± 0.5], 82 µg/mL [2.8 ± 1.93], 41 µg/mL [1.68 ± 0.16], 8 µg/mL [0.25 ± 0.6], 
4 µg/mL [0.23 ± 0.008], 0.8 µg/mL [0.016 ± 0.009], 0.4 µg/mL [0.046 ± 0.031], 0.08 µg/mL [0.017 ± 0.016], and 0.004 µg/mL [0.06 ± 0.04] (each data 
point represents the average of three separate studies (n = 3), and the error bars denote the standard error of measurements within each experi-
ment). b Plot of the linear region of the normalized decrease in fluorescence intensity of BSA-Au NCs (0.1× dilution) versus rifampicin concentration 
(each data point represents an average of three separate studies (n = 3); the error bars denote the standard error of measurements within each 
experiment). The excitation wavelength was set at 480 nm, and the emission wavelength was 640 nm.
Figure 4 a Fluorescence emission spectra of BSA-Au NCs (0.1× dilution) in the presence of primary TB drugs (100 µM each in the final concen-
tration). At 640 nm (emission wavelength): BSA-Au NCs (fluorescence intensity = 123.74 ± 1.56), NCs + rifampicin (83 µg/mL) (13.67 ± 0.33), 
NCs + pyrazinamide (12.3 µg/mL) (121.95 ± 0.69), NCs + ethambutol (27.7 µg/mL) (114.27 ± 1.28) and NCs + izoniazid (13.7 µg/mL) (127 ± 0.69) 
(each data point represents the average of three separate studies (n = 3), and the error bars denote the standard error of measurements within each 
experiment). b Comparison of the normalized decrease in fluorescence intensity of BSA-Au NCs (0.1× dilution) in the presence of primary TB drugs 
(100 µM each in final concentration). At 640 nm (emission wavelength): normalized quenching of NCs + rifampicin [(F0 − F)/F0 ~ 0.89 ± 0.006], 
NCs + pyrazinamide [0.013 ± 0.005], NCs + ethambutol [0.065 ± 0.008] and NCs + izoniazid [0.028 ± 0.007] (each data point represents the aver-
age of three separate studies (n = 3), and the error bars denote the standard error of measurements within each experiment). [In this work, (F0 − F)/
F0 = 1 indicates complete quenching and (F0 − F)/F0 = 0 indicates no quenching]. The excitation wavelength was set at 480 nm, and the emission 
wavelength was 640 nm.
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good efficacy as therapeutic agents [42–44]. Therefore, 
we tested the specificity of BSA-Au NCs toward detecting 
rifampicin using antibiotics with piperazine functional 
group such as ciprofloxacin [42], buspirone [43], ipsa-
pirone [44] (Additional file  1: Figure S10a). In addition, 
we also measured the fluorescence responses of some 
commonly used antibiotics and drugs (Additional file 1: 
Figure S10b). The average amount of residual rifampicin 
present in the patients’ urine is in the range of 45–55 µg/
mL [45]. Our results showed that at a final concentration 
of 50  µg/mL of rifampicin a nearly 60% decrease in the 
fluorescence intensity of the BSA-Au NCs was measured, 
whereas only a limited decrease in fluorescence intensity 
(less than 10%, p < 0.001) was observed for all the other 
antibiotics and drugs at the same concentration. There-
fore, BSA-Au NCs can be used for preferential sensing of 
rifampicin among other antibiotics administered at the 
same time. Additionally, the prepared BSA-Au NCs were 
freeze-dried and stored for 3  months before dispersion 
for the same experiment (Additional file  1: Figure S11). 
No drastic changes were observed, even after storage, 
indicating the excellent stability of the BSA-Au NC.
Tolerance to potentially interfering ions
In a real urine sample, the presence of ions might inter-
fere with rifampicin sensing. To evaluate the tolerance 
level to these ions, solutions containing specific ions 
were tested until the interfering substances had a mini-
mal effect on fluorescence quenching of the BSA-Au NCs 
(less than 5% change). The results from the potentially 
interfering substances are presented in the Additional 
file  1: Table S1 together with the typical ion concentra-
tions found in the real urine sample. The selective inter-
action of BSA-rifampicin was stronger than other ionic 
interferences. At a tenfold dilution, the interference from 
ions in urine is negligible.
Detection of rifampicin in spiked urine
After determining that the BSA-Au NCs have excellent 
sensitivity and specificity in sensing rifampicin, the next 
step was to determine the concentration of rifampicin 
in urine using BSA-Au NCs. Generally, evaluating the 
intake dosage of rifampicin for a patient requires urine 
collection over a long period of time (8–24  h) after 
ingestion of the drug followed by analysis in a labora-
tory equipped with sophisticated instrumentation. In the 
urine sample, the average indicative levels of rifampicin 
intake ranged from 45 to 55  µg/mL [45]. In our experi-
ment, various concentrations of rifampicin were spiked 
into 10 mL of fresh urine collected from a healthy indi-
vidual. A tenfold dilution of the urine sample containing 
rifampicin was used for the quantitative analysis via fluo-
rescence quenching (turn-off sensing mechanism). The 
recovery of rifampicin was estimated at greater than 85% 
in the concentration range normally present in actual 
urine samples (i.e., 5–60 µg/mL). Additional file 1: Table 
S2 presents the comparative results for determining 
rifampicin levels using other assays.
BSA‑Au NCs immobilized on a paper platform for detection 
of rifampicin in spiked urine
Disposable sensors are desirable in point-of-care appli-
cations. Therefore, we immobilized BSA-Au NCs on a 
wax-printed paper-based platform to conduct real-time 
monitoring of rifampicin in urine. The urine samples 
were collected from patients at the Tri-Service General 
Hospital in Taipei, Taiwan. The patients who contributed 
urine samples signed informed consent forms as required 
by the regulations of the Institutional Review Board of 
the Tri-Service General Hospital of Taipei, Taiwan. Ini-
tially, 30 µL of the prepared BSA-Au NCs were dropped 
in each well of the 96-well wax-printed paper platform 
and dried. The changes observed after the BSA-Au NCs 
were immobilized on the paper under ultraviolet (UV) 
light are shown in Figure  5a(A). The images were cap-
tured using a digital camera (Olympus, E-330), and the 
images were processed by MetaMorph software using 
only the ‘red’ color and center portion of each well to 
calculate the effective fluorescence intensity quenching 
ratios. The area without BSA-Au NCs (blank) was used 
as the background. Pale red fluorescence was clearly 
observed after immobilization of the BSA-Au NCs on 
the paper platform. Different amounts of rifampicin were 
spiked in the collected urine samples, and tenfold diluted 
urine samples were used for the quantitative analysis.
Increases in rifampicin concentration increased the 
fluorescence quenching of the imbedded BSA-Au NCs 
in the wax-printed paper sensor. Each colorimetric assay 
was performed using a total volume of 30  µL prepared 
BSA-Au NCs, and the evaluation was performed with 
a total of 30  µL spiked urine containing different con-
centrations of rifampicin. The amount of fluorescence 
quenching was lowest with spiked urine containing 
0.5 µg/mL rifampicin (Figure 5a(B)), followed by that of 
5 µg/mL (Figure 5a(C)), 10 µg/mL (Figure 5a(D)), 30 µg/
mL (Figure  5a(E)), 50  µg/mL (Figure  5a(F)), 100  µg/mL 
(Figure  5a(G)), 500  µg/mL (Figure  5a(H)) and 1000  µg/
mL (Figure 5a(I)). Our detection scheme can be further 
simplified via the use of a mobile imaging device that can 
determine the ratio of BSA-Au NCs quenching by cap-
turing the image intensity and perform analyses through 
an installed application [38–40]. This process elimi-
nates the need to install an image analyzer at the site of 
rifampicin detection. Figure  5b plots the data obtained 
from three different paper sensors with three independ-
ent data points for each concentration of rifampicin. Our 
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results show that even the minimum therapeutic dosage 
[45] (5 µg/mL) of rifampicin in the urine can be observed 
with the paper sensor platform. Therefore, the actual 
amount [45] (45–55 µg/mL) of rifampicin present in the 
urine sample can be monitored easily using this method-
ology. The results obtained for all data points were simi-
lar when the tests were performed with different paper 
platforms (Additional file 1: Table S3). This paper-based 
assay offers numerous advantages over solution-phase 
fluorescent probes, including its low cost, rapidity, sim-
plicity, robustness and ability to perform real-time moni-
toring of samples.
Conclusion
We have developed a robust, cost-effective and port-
able point-of-care medical diagnostic platform for the 
detection of rifampicin in urine based on the ability of 
rifampicin to quench the fluorescence of immobilized 
BSA-Au NCs on wax-printed paper. Water-soluble Au 
NCs were synthesized within 30 min at 70°C using BSA 
as a template. The prepared BSA-Au NCs possessed high 
fluorescence emission intensity and stability. The BSA-Au 
NCs showed remarkable selectivity towards rifampicin 
over other TB drugs. The fluorescent property of the 
BSA-Au NCs was retained after immobilization on paper, 
and the quenching of fluorescence by rifampicin in urine 
can be observed by the naked eye under UV irradiation. 
We demonstrated that a mobile imaging device can be 
used in data acquisition to capture the image intensity as 
well as data analysis to quantify the rifampicin. Therefore, 
the semi-quantitative assay presented here could be use-
ful for monitoring drug intake in TB patients on a regular 
basis and can act as a first line of detection to comple-
ment current techniques used to detect rifampicin in 
urine. The paper-based assay can also be used to detect 
other specific analytes via surface modification of the 
BSA in the BSA-Au NCs and has the potential for use in 
the monitoring of other diseases.
Methods
Materials
BSA was purchased from Sigma-Aldrich (A7906-10g). 
Hydrogen tetrachloroaurate(III) trihydrate (HAuCl4) 
and isonicotinic acid hydrazide were obtained from Alfa 
Aesar. Rifampicin was purchased from Sigma Aldrich 
(R3501-1g), pyrazinamide was obtained from Acros 
Organics, and ethambutol dihydrochloride was obtained 
from LKT Laboratories, Inc. Sodium hydroxide was 
obtained from Riedel–de Haen. All of the solvents and 
chemicals were used without further purification. Aque-
ous solutions were prepared using deionized water (DI) 
with a resistivity of 18.20 MΩ cm.
Instrumentation
A SpectraMax M2 (Molecular Devices) spectropho-
tometer was used to measure the visible ultraviolet 
(UV–Vis) absorbance of the protein–Au NCs and their 
fluorescence intensities with an excitation wavelength 
of 480  nm and emission wavelength of 640  nm. The 
FTIR (PerkinElmer Spectrum 100 FT-IR Spectrome-
ter) spectra were recorded to determine the structural 
changes before and after conjugation of Au with BSA. 
The STEM and TEM (JEOL JEM-2100 Field Emis-
sion Transmission Electron Microscope) images were 
Figure 5 a Test paper for the detection of rifampicin after modification (A) with BSA-Au NCs under UV light. The tenfold diluted urine samples 
with original rifampicin concentrations are as follows: (B) 0.5 µg/mL (fluorescence quenching ratio = 91% ± 1); (C) 5 µg/mL (82% ± 1.1); (D) 
10 µg/mL (81% ± 1.8); (E) 30 µg/mL (79% ± 3.4); (F) 50 µg/mL (78% ± 1.7); (G) 100 µg/mL (75% ± 0.3); (H) 500 µg/mL(73% ± 1.9); and (I) 1000 µg/
mL(69% ± 1.1). b Change in the fluorescence quenching ratio of the embedded BSA-Au NCs versus rifampicin concentration on the paper sensor 
(each data point represents an average of three separate studies (n = 3) in three different wax-printed 96-microplate paper platforms; three meas-
urements were taken in each micro-well, and the error bars denote the standard deviation of the reading).
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used to determine the size distributions and measure 
the dispersibility of the prepared nanoparticles. The 
MALDI-MS (MALDI TOF–TOF, Bruker, UltraflX-
treme) analysis was applied to reveal the number of 
Au atoms in the BSA-Au NCs. The ICP-MS (Thermo 
X-Series II) analysis was applied to determine the Au 
content of the purified BSA-Au NCs both in the pres-
ence and absence of rifampicin. A 90 Plus particle 
size analyzer (BIC) was used for the size distribution 
studies.
Synthesis of BSA‑stabilized gold nanoclusters
According to the reported protocol [41], 5  mL of an 
aqueous solution of HAuCl4 (10  mM) was added to 
5  mL BSA (50  mg/mL in water) under vigorous stir-
ring for 30 s. Next, the pH of the solution was adjusted 
to approximately 11.5 through the addition of NaOH 
(0.5 mL, 1 M). The reaction was conducted at 70°C and 
reached its maximum intensity after 30 min of reaction 
time with completion of the BSA-Au conjugation (Addi-
tional file 1: Figure S1), wherein the solution turned from 
pale yellow to dark red, thus indicating the formation of 
BSA-Au NCs. The BSA-Au NCs were freeze-dried and 
stored at 4°C and did not precipitate, even 3  months 
after re-dispersion in water. The use of the BSA-tem-
plate-mediated green synthesis route for the produc-
tion of fluorescent BSA-Au NCs through the proposed 
mechanism [41] considerably reduced the synthesis time 
and eliminated the need for further purification of toxic 
reagents.
Rifampicin detection procedure
Stock solutions (10  mM) of isoniazid (INZ), rifampicin 
(R), ethambutol (E) and pyrazinamide (P) were pre-
pared. Subsequently, 1 mL of the prepared BSA-Au NCs 
and 100  µL of the antibiotic solution were added to a 
bottle, and the volume was adjusted to 10 mL to a final 
antibiotic concentration of 100  µM. The fluorescence 
intensities were recorded immediately with an excita-
tion wavelength of 480  nm and emission wavelength of 
640  nm. The calibration curve for rifampicin was pre-
pared according to the normalized decrease in fluores-
cence intensity, which is defined as (F0 − F)/F, where F0 
and F are the maximum emission intensities of the BSA-
Au NC system in the absence and presence of rifampicin, 
respectively.
Characterization of BSA‑Au NCs
Field emission transmission electron microscopy was 
used on the prepared BSA-Au NCs to calculate the size 
distribution at 200  kV. The samples were prepared by 
applying the diluted solution (20-fold dilution from the 
prepared solution) onto formvar stabilized with a carbon 
TEM grid (200 mesh size; TED PELLA) followed by dry-
ing at room temperature. The MALDI-MS analysis was 
used to characterize the BSA conjugation with Au atoms. 
The ICP-MS analysis was applied to determine the Au 
content of the BSA-Au NCs both in the presence and 
absence of rifampicin.
BSA‑Au NCs on paper platform synthesis
Advantec chromatography paper sheets (grade No.1, 
Toyo Roshi Kaisha Ltd) were cut into standard A4 sheets 
that directly fit into the feed tray of a commercial solid 
ink printer (ColorQube™8570, Xerox Corporation). The 
ink printers were capable of printing patterns that serve 
as hydrophobic barriers after proper heating. Paper mir-
croplates were designed with a standard 96-well format. 
All of the measurements followed the “Corning Micro-
plate Selection guide” (Corning Inc., USA). The printed 
pattern of a 96-well plate was placed on a hot plate 
(Corning PC-420d, Corning Inc.) at 150°C for 2 min [12, 
13], which melted the wax and created a hydrophobic 
barrier because of vertical percolation of the wax in the 
paper. Each well was imbued with 30 µL of the prepared 
BSA-Au NCs and allowed to dry at 40°C for 30 min. The 
microplates were stored in the dark at room temperature 
(25–35°C).
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